Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe 3000

2 studies enrolling now · 12 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Chronic Low Back Pain (CLBP), Elevated Lp(a), Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight, T2D, Type 1 Diabetes, Type 2 Diabetes

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — Running, not enrolling
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Completed
• A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed